Arrowstreet Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Arrowstreet Capital’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-28,321	Closed	-$559K	–	2235
2019 Q4	$559K	Buy	+28,321	New	+$453K	﹤0.01%	1473
2018 Q3	–	Sell	-53,484	Closed	-$1.09M	–	1340
2018 Q2	$1.09M	Buy	53,484 +23,978	+81%	+$515K	﹤0.01%	785
2018 Q1	$536K	Buy	+29,506	New	+$492K	﹤0.01%	948
2017 Q4	–	Sell	-16,400	Closed	-$303K	–	1440
2017 Q3	$303K	Buy	+16,400	New	+$274K	﹤0.01%	1004
2017 Q2	–	Sell	-107,022	Closed	-$1.43M	–	1421
2017 Q1	$1.43M	Buy	+107,022	New	+$1.68M	0.01%	892
2016 Q4	–	Sell	-592,564	Closed	-$6.93M	–	2752
2016 Q3	$6.93M	Buy	+592,564	New	+$6.97M	0.02%	557
2014 Q2	–	Sell	-210,743	Closed	-$2.46M	–	1256
2014 Q1	$2.46M	Buy	210,743 +106,714	+103%	+$1.81M	0.01%	610
2013 Q4	$1.84M	Buy	104,029 +37,227	+56%	+$626K	0.01%	686
2013 Q3	$961K	Buy	+66,802	New	+$1.02M	0.01%	683

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Arrowstreet Capital's MNTA Position: Q1 2020 in Review

Arrowstreet Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2020, closing a stake of 28,321 shares — an estimated $559K sold.

Arrowstreet Capital first reported a position in MNTA in Q3 2013 and held it in 9 quarters. The position peaked at $6.93M in Q3 2016. 199 funds tracked by Wall St. Rank hold MNTA as of Q1 2020.

Arrowstreet Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Arrowstreet Capital sold 28,321 Momenta Pharmaceuticals, Inc. shares in Q1 2020, an estimated $559K.
Arrowstreet Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2013 and held it in 9 quarters.
Arrowstreet Capital's Momenta Pharmaceuticals, Inc. position peaked at $6.93M in Q3 2016.
199 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2020.

Based on Arrowstreet Capital's 13F filing for Q1 2020, filed 15 May 2020.